Jump to content

Search the Community

Showing results for tags 'COVID-19 vaccines'.

  • Search By Tags

    Type tags separated by commas.
  • Search By Author

Content Type


  • Vaccine Safety Communication eLibrary

Find results in...

Find results that contain...

Date Created

  • Start


Last Updated

  • Start


Filter by number of...


  • Start



First name

Last name






I am joining because:

  1. Preventing and addressing health misinformation is a major priority for the Surgeon General. In a new Surgeon General’s Advisory and Community Toolkit for Addressing Health Misinformation, the Surgeon General is warning the American public about the urgent threat of health misinformation and calling for a whole-of-society approach to address health misinformation during the COVID-19 pandemic and beyond. During the COVID-19 pandemic, people have been exposed to an abundance of information from a large number of sources. Misinformation has caused confusion and led people to decline COVID-19 vaccines, reject public health measures such as masking and physical distancing, and use unproven treatments.
  2. The National Public Health Information Coalition (NPHIC) and the Association of Immunization Managers (AIM) have partnered to increase information sharing and collaboration between public information officers and immunization program managers related to COVID-19, flu, and routine vaccination. Through this resource portal, we will share talking points, messages, and other materials to support your immunization-related communications efforts. Funding for this effort was provided by the CDC Foundation.
  3. Resources including: factsheet for health workers job aid for COVID-19 vaccine administration
  4. Thrombotic Thrombocytopenia Syndrome (TTS) has emerged as a new adverse event following immunization in individuals vaccinated with COVID-19 non-replicant adenovirus vector-based vaccines (AstraZeneca COVID-19 ChAdOx-1 vaccine and Johnson & Johnson (J&J) Janssen COVID-19 Ad26.COV2-S vaccine). TTS is a serious and life-threatening adverse event. WHO has issued this interim emergency guidance to increase awareness about TTS in the context of COVID-19 vaccination and help healthcare providers in the assessment and management of potential TTS cases. Knowledge about TTS following vaccination with a COVID-19 adenovirus vector-based vaccine is rapidly evolving. WHO will continue to monitor the situation closely for any changes that may affect this interim guidance and will update the guidance as needed.
  5. Schools are trusted institutions in their communities and can play a vital role in promoting COVID-19 vaccination. From setting up a school-located vaccination clinic to engaging with trusted community partners, there are many ways schools can help to increase vaccination uptake among students and the broader community. To support a safe and healthy return to school, the Public Health Communications Collaborative and the COVID Collaborative have created a one-page resource for school administrators, educators, and staff with resources created or curated by the CDC.
  6. FAQs regarding the flu season 2021-2022. The questions and answers include information on the flu vaccine, the viral strains circulating, the flu vaccine coverage, information on seasonal flu in the context of COVID-19, as well as information for healthcare professionals. Resource available in Spanish.
  7. IMAC COVID-19 has been contracted by the Ministry of Health to provide education and support to all health professionals and allied workforces across New Zealand during the rollout. They are supporting vaccinators and the healthcare workforce with training and information to administer COVID-19 vaccines in New Zealand. With their team based around the country, they provide on-the-ground support and customized education for engagement in different community settings, in addition to the online learning courses. The course can be adapted and used by other colleagues in other locations.
  8. Wondering how the mRNA vaccines are processed? Check out our newly released animation, “How mRNA Vaccines Work.”
  9. The latest on the COVID-19 global situation and monitoring vaccine safety. It is part of a larger pool of resources related to COVID-19 pandemic.
  10. Educational video on thrombosis with thrombocytopenia syndrome following adenoviruses vaccines against COVID-19.
  11. Training module The training module, in the form of presentation slides, provides a structured approach to assist health workers with interpersonal communication during COVID-19 vaccination consultations and is tailored to specific patient positions on vaccination. Participants are guided through 6 learning parts focusing on a combination of theory and practical skill building scenarios. Relevant COVID-19 vaccine and vaccination resources for health workers are provided to support vaccination consultations. This training is primarily for frontline health workers who will be vaccinators. Facilitator’s guide The Facilitator’s guide is designed to accompany the training module, providing detailed explanations and resources for all parts of the training module. A pre and post training self-reflection survey and post-training evaluation tool is also included. The facilitator’s guide is intended for training facilitators or Trainers of Trainers (ToTs) who will be conducting the training at the country level. Job aid The job aid is an interpersonal communication tool designed to support health workers in facilitating structured and collaborative COVID-19 vaccination conversations with patients, aiming to increase vaccine confidence and acceptance. It is intended for use in vaccination consultation settings.
  12. CDC regularly creates reports about the status of COVID-19 vaccine confidence in the United States, emphasizing major themes that influence vaccine confidence and uptake. The reports include analyses of multiple quantitative and qualitative data sources, ranging from social listening and web metrics to immunization survey data and CDC-INFO inquiries. The reports seek to identify emerging issues of misinformation, disinformation, and places where intervention efforts can positively increase vaccine confidence across the United States.
  13. The National Foundation for Infectious Diseases (NFID) convened a multidisciplinary group of experts at a virtual roundtable in January 2021 to share research, insights, and best practices for improving and harmonizing communication to the public about the evolving COVID-19 pandemic and the importance of following evidence-based public health prevention measures.
  14. COVAX, the largest and most complex global distribution of vaccines is under way, protecting the most vulnerable from COVID-19, wherever they are in the world. In order to end the acute phase of the pandemic and protect the world against the spread of new variants, the global roll-out must continue at unprecedented speed. The COVAX AMC has raised US$ 9.6 billion to date. This vital funding will enable COVAX to protect almost 30% of the population in 91 lower-income economies. But the COVAX delivery schedule has been hit hard by supply delays, and faces a supply shortfall of 190 million doses. To change the course of the pandemic, plug this short-term gap and help ensure equitable access to vaccines through COVAX: o Countries that have doses need to share them now – not later, when countries’ demand and ability to absorb doses will be met by hundreds of millions of doses that will be available through COVAX Facility deals. o Manufacturers need to prioritise COVAX. o Multilateral development banks must urgently release the funds to pay for health system preparedness to ensure countries can absorb the doses delivered. We call on the international community to reaffirm its support for the COVAX AMC and act urgently as One World Protected: Committed to Deliver.
  15. This document provides answers to some of the most frequently asked questions around coronavirus and the Covid-19 vaccine for a general public audience. This document will be updated regularly, and changes will be highlighted in yellow. Please look out for further iterations from your regional NHSEI communications team, and if in any doubt please check with them that you are using the latest version. Contents include: Coronavirus, About the Covid-19 vaccine, Covid-19 vaccine – eligibility, Covid-19 vaccine – timing, Covid-19 vaccine safety, Covid-19 vaccine side-effects, Covid-19 vaccine effectiveness, Covid-19 vaccine ingredients, Vaccine hesitancy, Second doses.
  16. A vaccine to prevent COVID-19 is likely to be the most effective way to control the pandemic. Scientists across the world have worked to develop vaccines which have then been rigorously tested for safety and efficacy. Those with a role in delivering/supporting the COVID-19 vaccine programme need to be knowledgeable, confident and competent in order to promote confidence in the vaccination programme and deliver the vaccine safely. The purpose of this pack is to ensure you have all the resources and information you need to hand, acting as a ‘go to guide’ to support you when talking with patients who are eligible for a Covid-19 vaccination but are showing signs of hesitancy. People may be concerned about or refusing the vaccine due to worries, fears, unclear about messages or for many other reasons. It’s important to understand that people will have their point of view and it may take time to talk through their concerns. Using Motivational Interviewing techniques, listening skills and sharing factual information about Covid-19 and the vaccine may help to encourage people and offer reassurance.
  17. Qui peut se faire vacciner aujourd’hui contre le Covid-19 ? Comment prendre rendez-vous pour cette vaccination ? Quels sont les effets secondaires des vaccins autorisés en France ? Comment la sécurité des vaccins est-elle garantie ? La campagne vaccinale contre le Covid-19 se poursuit et suscite toujours de nombreuses interrogations. Franceinfo s'efforce d’y répondre dans le cadre de son opération #OnVousRépond. Vous trouverez ici nos réponses aux questions les plus fréquentes sur les vaccins contre le Covid-19. Il est possible de compléter avec les sites des autorités sanitaires, les travaux des sociétés savantes (comme ce dossier de la Société de pathologie infectieuse de langue française) et bien entendu auprès de son médecin.
  18. La pandémie de Covid-19 ayant causé plus de 100 millions de cas et plus de 2,3 millions de morts à l’échelle mondiale, la publication des résultats des études pivot des premiers candidats-vaccins contre la Covid-19 a été une source d’espoir pour la communauté internationale. De nombreux pays ont rapidement initié une campagne vaccinale contre la Covid19 ; plus de 150 millions de doses ont été administrées dans le monde au 12 février 2021 (https://ourworldindata.org/covid-vaccinations). De nombreuses questions ont été soulevées en France, à la fois par les décideurs en Santé publique, mais aussi très vite par les soignants et acteurs de terrain, en charge d’informer la population, de définir et repérer les personnes prioritaires et de mettre en place la campagne vaccinale en France. Devant cette demande forte d’éclairage simple et objectif des données disponibles, la Société de Pathologie Infectieuse de Langue Française (SPILF) a été sollicitée pour élaborer un document d’information à destination des professionnels de santé.
  19. This section is an ongoing compilation of tough questions related to COVID-19, with suggested answers. Many of these topics are sensitive and often politicized. The document is designed to provide message guidance and framing for public health officials and others, and it is regularly updated to reflect new developments and emerging issues.
  20. The COVID-19 Vaccine Communications Toolkit was developed as a guide through the steps involved in planning, designing and executing a vaccine communications plan and campaign. The following information highlights the strategies and experiences of health care marketing and communications professionals and emerged from the December 2020 Society for Health Care Strategy & Market Development (SHSMD) Vaccine Distribution and Communications: A SHSMD Member Collaborative Workshop. This information will be updated as new resources, tools and examples become available.
  21. What you need to know COVID-19 vaccines are safe and effective. Millions of people in the United States have received COVID-19 vaccines under the most intense safety monitoring in U.S. history. CDC recommends you get a COVID-19 vaccine as soon as you are eligible.
  22. Many people have questions about the coronavirus disease 2019 (COVID-19) vaccines. As vaccine recipients’ most-trusted source of information on vaccines, you play a critical role in helping vaccine recipients understand the importance of vaccination and that COVID-19 vaccines are safe and effective. The information on this page will help you share clear and accurate information about COVID-19 vaccines, raise awareness about the benefits of vaccination, and address common questions and concerns about what to expect when getting vaccinated.
  23. Questions and answers regarding the Emergency Use Listing (EUL) procedure for vaccines against COVID-19.
  24. Information about COVID-19 vaccines is quickly evolving and WHO will aim to update this Q&A on an ongoing basis, as we learn more.
  • Create New...

Important Information

We have placed cookies on your device to help make this website better. You can adjust your cookie settings, otherwise we'll assume you're okay to continue. - Terms of Use - Privacy Policy - Guidelines